Analystreport

VBI Vaccines Inc (NASDAQ: VBIV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock.

VBI Vaccines, Inc. - Ordinary Shares  (VBIV) 
Last vbi vaccines, inc. - ordinary shares earnings: 11/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: vbivaccines.com/investors